# A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

> **NCT03697109** · PHASE3 · COMPLETED · sponsor: **Corcept Therapeutics** · enrollment: 152 (actual)

## Conditions studied

- Cushing Syndrome

## Interventions

- **DRUG:** Relacorilant
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03697109
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-15
- **Primary completion:** 2024-04-08
- **Final completion:** 2024-04-15
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03697109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03697109, "A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome". Retrieved via AI Analytics 2026-06-27 from https://api.ai-analytics.org/clinical/NCT03697109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*